Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 in adults with Fragile X Syndrome
NCT01253629Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Primary completion
- Aug 2013
- Countries
- 10
01
Overview
A Phase 2 trial of mavoglurant in Fragile X syndrome (FXS), sponsored by Novartis. Started Nov 2010; status: completed.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01253629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253629.